THE EDITIONS
Keep what we knew, when we knew it.
Each edition preserves its readings, evidence and topic states together.
WEEKLY / EDITION RECORD
Reading Change, Making the Next Decision
3 readings · 26 topics
WEEKLY / EDITION RECORD
Reading Change, Making the Next Decision
3 readings · 23 topics
WEEKLY / EDITION RECORD
Reading Change, Making the Next Decision
5 readings · 20 topics
WEEKLY / EDITION RECORD
The Work That Makes Development Possible
3 readings · 17 topics
WEEKLY / EDITION RECORD
Investing in What Comes After Discovery
5 readings · 14 topics
WEEKLY / EDITION RECORD
Testing predictions in experiments, clinical care and business. — expanded edition
6 readings · 10 topics
WEEKLY / EDITION RECORD
Testing predictions in experiments, clinical care and business.
4 readings · 9 topics
WEEKLY / EDITION RECORD
Screening, research access, and memory in a changing brain.
3 readings · 5 topics
Issue insights
· Shared knowledge and the data each patient still needs ↗
· Are we removing the reasons drugs fail from our experiments? ↗
· Research AI cannot be priced by the number of candidates it produces ↗
· How should we pay for the work that makes a treatment possible? ↗
· Investing in What Comes After Discovery ↗
Compare editions
Memory resilience
Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory. → Compare sleep, representational drift and selective synaptic perturbation to investigate changes compatible with memory.
0 new events · Reading unchangedShield: screening adoption
Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance. → Guardant announced Shield’s inclusion in EviCore guidelines, effective January 1, 2027. This is not an update to detection performance.
0 new events · Reading unchangedTherapy & companion diagnostics
Linked approval; uptake and payment open → Linked approval; uptake and payment open
0 new events · Reading unchangedCompute for science
A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions. → A collaboration route exists from Japan. Check funding, compute allocation, disclosure and IP conditions.
0 new events · Reading unchangedAI–scientist collaboration
Institutional report; independent verification open → Institutional report; independent verification open
0 new events · Reading unchangedAfter AI Finds a Candidate, What Gets Paid For?
The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs. → The existing comparison of experimental services and rights to discovery assets now includes Ginkgo’s contribution of lab time and protein-testing services to NSF X-Labs.
0 new events · Reading unchangedWho Will Build the Systems to Oversee Clinical AI?
ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation. → ARPA-H announced ADVOCATE development plans covering patient-facing AI, supervision, implementation and independent evaluation.
0 new events · Reading unchangedHow Far Can Human Neural Tissue Compensate for Lost Function?
A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons. → A study examined human cortical organoid growth, connections, activity and behavior in mice with major developmental depletion of cortical and hippocampal excitatory neurons.
0 new events · Reading unchangedCan measuring brain function help us choose an antidepressant?
In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes. → In SMART-D’s main analysis of 47 participants over eight weeks, selecting a marker-consistent drug did not demonstrate better outcomes.
0 new events · Reading unchangedWhat Do New Cells Contribute to a Brain That Preserves Memories?
A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts. → A human postmortem study suggested stalled neurogenesis associated with depression. A separate mouse study found that greater survival of new neurons improved discrimination of similar contexts.
0 new events · Reading unchangedSignatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial. → Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
0 new events · Reading unchangedTransporting Cell Therapies Without Refrigeration
BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years. → BoSS announced three development teams and independent testing by ATCC, with up to $87 million planned over four years.
0 new events · Reading unchangedDifferent Causes, Similar Psychiatric Symptoms: Protecting the Receptor
Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial. → Receptor-protection evidence spans cultured cells and animals; ART5803 has entered a Phase 2a patient trial.
0 new events · Reading unchangedWhat Does Chugai Still See in a Drug Roche Is Walking Away From?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal. → As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
0 new events · Reading unchangedInvesting in another company's drug to advance your own
The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues. → The partnership and combination-development record now includes BNT113. In HPV16-positive head and neck cancer, the pembrolizumab combination did not establish PFS superiority; assessment of OS, the other prespecified primary endpoint, continues.
0 new events · Reading unchangedWhat does an AI business sell when it helps run a clinical trial?
SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights. → SURPASS calls for validation in real trials, with initial public support and a route to continuing operations. Participation does not establish an automatic allocation of drug development or commercial rights.
0 new events · Reading unchangedUsing the same lesson across different actions, without confusing them
Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference. → Mouse tasks with different actions and a shared reward delay showed shared cortical activity and task-dependent cerebellar separation that preserved temporal structure. A computational model combined faster learning with reduced interference.
0 new events · Reading unchangedChanging treatment before scans show progression: a new relationship between breast cancer drugs and blood tests
European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression. → European certification was added for Guardant360 CDx. Earlier switching prolonged PFS in selected SERENA-6 patients, while SERENA-4 under different conditions missed its primary endpoint. FDA requires confirmation comparing early switching with switching at progression.
0 new events · Reading unchangedDoes an antibody that binds well make a good development candidate?
A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays. → A common-condition study of 511 sequences from 29 organizations found different performance in improvement and ranking tasks. Cradle’s high-affinity candidate passed the aggregate threshold but retained concerns in individual developability assays.
0 new events · Reading unchangedCan the same information remain readable as neural activity changes?
Flexible electrodes tracked the same mouse neurons over months. Aligning activity across recording days improved decoding of temporal information in a repeated movie. The analysis also used responses from the new day. → Flexible electrodes tracked the same mouse neurons over months. Aligning activity across recording days improved decoding of temporal information in a repeated movie. The analysis also used responses from the new day.
0 new events · Reading unchangedEnspryng expands into thyroid eye disease: a different target and a different way to treat
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training. → The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
0 new events · Reading unchangedLooking across diseases for drugs that treat fibrosis
3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences. → 3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
0 new events · Reading unchangedWhy does the same inflammation affect some fetuses but not others?
Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid. → Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid.
0 new events · Reading unchangedFrom testing a patient's cancer to making their treatment
Not tracked → The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
0 new events · Reading or next evidence changedBuilding experimental data together for cell AI
Not tracked → The Virtual Biology Initiative expands joint experimental-data infrastructure. Separately, Arc’s 2026 challenge tests response prediction without providing perturbation outcomes in the target cells.
0 new events · Reading or next evidence changedACE levels are lower. Which functions have changed?
Not tracked → The study reports lower ACE protein abundance associated with early-stage psychosis and treatment resistance, but no significant group difference in enzyme activity per unit serum volume.
0 new events · Reading or next evidence changed